Insulin resistance in T2D increases FoxO1 activation in metabolic tissues including liver, skeletal muscle, adipose tissue, pancreas, and brain, which underscores FoxO1’s potential clinical relevance. Here, FOXO1 is linked to type 2 diabetes mellitus.